- Home
- MLAB vs KURA Comparison
MLAB vs KURA Comparison
Compare MLAB & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLAB
- KURA
- Stock Information
- Founded
- MLAB 1982
- KURA 2014
- Country
- MLAB United States
- KURA United States
- Employees
- MLAB N/A
- KURA N/A
- Industry
- MLAB Industrial Machinery/Components
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MLAB Industrials
- KURA Health Care
- Exchange
- MLAB Nasdaq
- KURA Nasdaq
- Market Cap
- MLAB 524.2M
- KURA 492.9M
- IPO Year
- MLAB N/A
- KURA N/A
- Fundamental
- Price
- MLAB $95.82
- KURA $5.85
- Analyst Decision
- MLAB Hold
- KURA Strong Buy
- Analyst Count
- MLAB 2
- KURA 12
- Target Price
- MLAB $130.00
- KURA $24.50
- AVG Volume (30 Days)
- MLAB 126.1K
- KURA 1.3M
- Earning Date
- MLAB 08-04-2025
- KURA 08-07-2025
- Dividend Yield
- MLAB 0.67%
- KURA N/A
- EPS Growth
- MLAB N/A
- KURA N/A
- EPS
- MLAB N/A
- KURA N/A
- Revenue
- MLAB $240,978,000.00
- KURA $67,991,000.00
- Revenue This Year
- MLAB $6.28
- KURA $109.86
- Revenue Next Year
- MLAB $5.93
- KURA $107.90
- P/E Ratio
- MLAB N/A
- KURA N/A
- Revenue Growth
- MLAB 11.47
- KURA N/A
- 52 Week Low
- MLAB $83.68
- KURA $5.41
- 52 Week High
- MLAB $155.12
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- MLAB 36.61
- KURA 40.44
- Support Level
- MLAB $87.80
- KURA $5.56
- Resistance Level
- MLAB $105.59
- KURA $7.17
- Average True Range (ATR)
- MLAB 4.00
- KURA 0.38
- MACD
- MLAB -0.44
- KURA -0.06
- Stochastic Oscillator
- MLAB 43.12
- KURA 6.05
About MLAB Mesa Laboratories Inc.
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.